GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CellSource Co Ltd (TSE:4880) » Definitions » Net Current Asset Value

CellSource Co (TSE:4880) Net Current Asset Value : 円229.32 (As of Jan. 2024)


View and export this data going back to 2019. Start your Free Trial

What is CellSource Co Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

CellSource Co's net current asset value per share for the quarter that ended in Jan. 2024 was 円229.32.

The historical rank and industry rank for CellSource Co's Net Current Asset Value or its related term are showing as below:

TSE:4880' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 5.45   Med: 24.83   Max: 52.13
Current: 5.93

During the past 7 years, the highest Price-to-Net-Current-Asset-Value Ratio of CellSource Co was 52.13. The lowest was 5.45. And the median was 24.83.

TSE:4880's Price-to-Net-Current-Asset-Value is ranked worse than
64.65% of 1041 companies
in the Biotechnology industry
Industry Median: 3.97 vs TSE:4880: 5.93

CellSource Co Net Current Asset Value Historical Data

The historical data trend for CellSource Co's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CellSource Co Net Current Asset Value Chart

CellSource Co Annual Data
Trend Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
Net Current Asset Value
Get a 7-Day Free Trial 82.17 100.67 123.53 174.64 248.55

CellSource Co Quarterly Data
Oct18 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Net Current Asset Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 179.00 188.42 182.65 248.55 229.32

Competitive Comparison of CellSource Co's Net Current Asset Value

For the Biotechnology subindustry, CellSource Co's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CellSource Co's Price-to-Net-Current-Asset-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CellSource Co's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where CellSource Co's Price-to-Net-Current-Asset-Value falls into.



CellSource Co Net Current Asset Value Calculation

CellSource Co's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Oct. 2023 is calculated as

Net Current Asset Value Per Share(A: Oct. 2023 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(5589.181-677.739-0-0)/19.7605
=248.55

CellSource Co's Net Current Asset Value (NCAV) per share for the quarter that ended in Jan. 2024 is calculated as

Net Current Asset Value Per Share(Q: Jan. 2024 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(5388.348-846.642-0-0)/19.8055
=229.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CellSource Co  (TSE:4880) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


CellSource Co Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of CellSource Co's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


CellSource Co (TSE:4880) Business Description

Traded in Other Exchanges
N/A
Address
Shibuya Mitake Building, 2nd Floor, 1-19-5 Shibuya, Shibuya-ku, Tokyo, JPN, 150-0002
CellSource Co Ltd is engaged in contract manufacturing of fat-and blood-derived organizations and cells from medical institutions, provision of legal support to medical institutions in the regenerative medicine business. The company is also involved in sales of medical devices, and sales of own-brand cosmetics in the consumer business.

CellSource Co (TSE:4880) Headlines

No Headlines